Jefferies Starts Oruka Therapeutics (ORKA) at Buy

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 7/15/2026

1. SPY
2. PYPL
3. JPM
4. AMZN
5. MSFT
6. GS
7. GOOGL
8. BAC
9. IBM
10. SPCX

Go back to Jefferies Starts Oruka Therapeutics (ORKA) at Buy

Oruka Therapeutics Announces $200 Million Private Placement

September 12, 2024 7:05 AM EDT

MENLO PARK, Calif., Sept. 12, 2024 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (Oruka or the Company) (Nasdaq: ORKA), a biotechnology company developing novel biologics designed to set a new standard for the treatment of chronic skin diseases, including plaque psoriasis, today announced that it has entered into a securities purchase agreement for a private investment in public equity (PIPE) financing that is expected to result in gross proceeds of approximately $200 million to the Company, before placement agent fees and offering expenses. The PIPE financing included participation from both new and existing investors, including a large investment manager,... More

Oruka Therapeutics Announces Accelerated Clinical Timelines and Upcoming Presentation at EADV Supporting ORKA-001’s Profile as a Potentially Best-in-Class Half-Life Extended Antibody Targeting IL-23

September 12, 2024 7:00 AM EDT

ORKA-001, a novel half-life extended IL-23p19 monoclonal antibody (mAb), first-in-human dosing now expected first quarter 2025

ORKA-002, a novel half-life extended IL-17A/F mAb, first-in-human dosing now expected third quarter 2025

New preclinical data on ORKA-001 to be presented at EADV in September showing robust preclinical activity including a half-life in NHPs of over 30 days

MENLO PARK, Calif., Sept. 12, 2024 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (Oruka) (Nasdaq: ORKA), a biotechnology company developing novel biologics designed to set a new standard for the... More